JP2002504091A - コルチコステロイドに対する応答性を調整するための方法及び組成物 - Google Patents

コルチコステロイドに対する応答性を調整するための方法及び組成物

Info

Publication number
JP2002504091A
JP2002504091A JP54063398A JP54063398A JP2002504091A JP 2002504091 A JP2002504091 A JP 2002504091A JP 54063398 A JP54063398 A JP 54063398A JP 54063398 A JP54063398 A JP 54063398A JP 2002504091 A JP2002504091 A JP 2002504091A
Authority
JP
Japan
Prior art keywords
patient
corticosteroids
patients
acid
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54063398A
Other languages
English (en)
Japanese (ja)
Inventor
セクート，レス
カーター，アダム
ガユル，タリク
バーナジー，スバシス
イー． トレイシー，ダニエル
Original Assignee
ベーアーエスエフ アクツィエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by ベーアーエスエフ アクツィエンゲゼルシャフト filed Critical ベーアーエスエフ アクツィエンゲゼルシャフト
Publication of JP2002504091A publication Critical patent/JP2002504091A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP54063398A 1997-03-18 1998-03-12 コルチコステロイドに対する応答性を調整するための方法及び組成物 Pending JP2002504091A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US08/820,692 1997-03-18
US1634698A 1998-01-30 1998-01-30
US09/016,346 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (1)

Publication Number Publication Date
JP2002504091A true JP2002504091A (ja) 2002-02-05

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54063398A Pending JP2002504091A (ja) 1997-03-18 1998-03-12 コルチコステロイドに対する応答性を調整するための方法及び組成物

Country Status (20)

Country Link
EP (1) EP0998300A1 (zh)
JP (1) JP2002504091A (zh)
KR (1) KR20000076420A (zh)
CN (1) CN1269722A (zh)
AU (1) AU734756B2 (zh)
BG (1) BG103808A (zh)
BR (1) BR9810409A (zh)
CA (1) CA2282845A1 (zh)
DE (1) DE998300T1 (zh)
ES (1) ES2146192T1 (zh)
HU (1) HUP0104439A3 (zh)
ID (1) ID22975A (zh)
IL (1) IL131815A0 (zh)
NO (1) NO994506L (zh)
NZ (1) NZ337769A (zh)
PL (1) PL336464A1 (zh)
SI (1) SI20110A (zh)
SK (1) SK122199A3 (zh)
TR (1) TR199902615T2 (zh)
WO (1) WO1998041232A2 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
JP2006503905A (ja) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
JP2015155423A (ja) * 2006-10-17 2015-08-27 ネオセティクス，インク． 甲状腺眼症の治療のための方法、組成物及び製剤

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE69825976T2 (de) * 1997-10-31 2005-09-01 Wyeth Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
CA2323439A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation VACCINE BASED ON INTERFERON GAMMA INDUCTION FACTOR AND USE THEREOF FOR PROVIDING PROTECTION IMMUNITY AGAINST MULTIPLE SCLEROSIS
CA2353520C (en) * 1998-12-09 2006-04-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
CN1346344A (zh) 1999-03-16 2002-04-24 西托维亚公司 取代的2－氨基苯甲酰胺天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其应用
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
JP2002541237A (ja) 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
TW201305214A (zh) 2000-02-10 2013-02-01 Abbott Gmbh & Co Kg 與人類間白素－１８結合之抗體，及其製法及用途
JP2003535148A (ja) * 2000-06-06 2003-11-25 グラクソ グループ リミテッド 癌の治療方法
WO2001097815A2 (de) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Verwendung von glukokortikosteroiden zur herstellung eines medikamentes für die behandlung von haarschwund
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
UA80676C2 (en) * 2001-01-29 2007-10-25 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy
ATE451930T1 (de) * 2001-05-16 2010-01-15 Yeda Res & Dev Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP1448205B1 (en) * 2001-10-05 2011-03-23 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
EP2274333A4 (en) 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2646012A4 (en) 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
FR2651678B1 (fr) * 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NZ306281A (en) * 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503905A (ja) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
US7887802B2 (en) 2004-07-16 2011-02-15 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
JP2015155423A (ja) * 2006-10-17 2015-08-27 ネオセティクス，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
JP2015163612A (ja) * 2006-10-17 2015-09-10 ネオセティクス，インク． 甲状腺眼症の治療のための方法、組成物及び製剤

Also Published As

Publication number Publication date
KR20000076420A (ko) 2000-12-26
WO1998041232A2 (en) 1998-09-24
ID22975A (id) 1999-12-23
NO994506L (no) 1999-11-17
WO1998041232A3 (en) 2000-10-05
CN1269722A (zh) 2000-10-11
NO994506D0 (no) 1999-09-17
PL336464A1 (en) 2000-06-19
HUP0104439A2 (hu) 2002-04-29
AU734756B2 (en) 2001-06-21
IL131815A0 (en) 2001-03-19
AU6760498A (en) 1998-10-12
NZ337769A (en) 2002-09-27
EP0998300A1 (en) 2000-05-10
ES2146192T1 (es) 2000-08-01
SK122199A3 (en) 2000-12-11
BG103808A (en) 2000-07-31
CA2282845A1 (en) 1998-09-24
SI20110A (sl) 2000-06-30
HUP0104439A3 (en) 2002-08-28
DE998300T1 (de) 2001-03-01
BR9810409A (pt) 2000-08-22
TR199902615T2 (xx) 2000-03-21

Similar Documents

Publication Publication Date Title
JP2002504091A (ja) コルチコステロイドに対する応答性を調整するための方法及び組成物
US6054487A (en) Methods and compositions for modulating responsiveness to corticosteroids
JP4504570B2 (ja) 炭素環式カリウムチャンネル阻害薬
JP4676676B2 (ja) カスパーゼ阻害剤としての複素環ジカルバミド
JPH10501244A (ja) インターロイキン−１β変換酵素の二環式ラクタム阻害剤
JPH09511249A (ja) インターロイキン阻害剤としてのピリミジニル誘導体
WO2001019373A2 (en) Methods and compositions for modulating responsiveness to corticosteroids
JPH10511935A (ja) タチキニンアンタゴニスト
JP2001517246A (ja) α▲下４▼β▲下１▼媒介細胞接着の阻止剤
JP2002502873A (ja) 化合物
JP2001518922A (ja) アリール−またはヘテロアリール−スルホンアミドで置換されたヒドロキサム酸誘導体、その製法およびその医薬としての使用
JP2002509153A (ja) インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
TW201802110A (zh) 新穎環孢素衍生物及其用途
JP2000508666A (ja) 成長ホルモン放出特性を有する化合物
JPH11511481A (ja) 免疫抑制活性を有するトリテルペン誘導体
JP2003532727A (ja) Ｃｄ２３の阻害剤としてのｎ−スルホニルヒドロキサム酸誘導体
JP3922431B2 (ja) 可溶性ヒトｃｄ２３形成阻害剤としてのヒドロキサム酸誘導体
JP4181220B2 (ja) Ｉｌ―４およびｇ―ｃｓｆに影響するナフチリジン類
JP2021523138A (ja) Ｉｌ−２３抗体を使用してうつを治療する方法
JPH08511783A (ja) Ｎ−置換アザ複素環式カルボン酸類とそのエステル類
JPH06271533A (ja) 免疫抑制剤としての新規なアミノメチレン誘導体
CZ312799A3 (cs) Přípravky pro modulaci reakce na kortikosteroidy
MXPA99008433A (en) Methods and compositions for modulating responsiveness to corticosteroids
JP2003012626A (ja) アルキルアミド化合物
ES2243783T3 (es) Derivados de sulfona apropiadas para el tratamiento de enfermedades autoinmunes y alergias.